Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
BioConsortia has hired Dr. Damian Curtis to head synthetic biology platform for next generation biopesticides, biostimulants and fertilizers.
Did Hedge Funds Make The Right Call On Exelixis, Inc. (EXEL) ?
02:45pm, Monday, 13'th Jul 2020
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail invest
2 Stocks to Buy if You're Worried About Another Market Crash
11:16am, Friday, 10'th Jul 2020
Here are two stocks that might do just that: Exelixis (NASDAQ: EXEL) and Netflix (NASDAQ: NFLX). Its revenue largely depends on just one product: Cabometyx, a tyrosine kinase inhibitor (TKI) that spe
Got $3,000? 3 Growth Stocks You Won't Regret Buying
09:51am, Friday, 10'th Jul 2020
Although stock market corrections are part of the investing cycle, no investor, tenured or not, could have been prepared for what 2020 has offered. In about a four-month time span, the stock market h
5 Booming Biotech Stocks to Buy
04:36pm, Friday, 03'rd Jul 2020
These five biotech stocks have already gone on heaters of 30% or more in 2020, and all of them still have plenty of upside to spare.
Revance Positive Data And Other News: The Good, Bad And Ugly Of Biopharma
02:07am, Friday, 03'rd Jul 2020
Revance reports positive results from facial skin lines trial. Exelixis starts phase 3 prostate cancer trial. Galectin starts patient enrolment in NASH phase 2/
Exelixis (EXEL) Receives a Buy from William Blair - Markets
03:58pm, Thursday, 02'nd Jul 2020
In a report issued on June 30, Andy Hsieh from William Blair reiterated a Buy rating on Exelixis (EXEL –
Invesco Ltd. Raises Holdings in Exelixis, Inc. (NASDAQ:EXEL)
06:14am, Thursday, 02'nd Jul 2020
Invesco Ltd. lifted its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 56.7% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 936,146 shares of the
Ipsen : collaboration clinique pour le cabozantinib | Zone bourse
06:04am, Thursday, 02'nd Jul 2020
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), today announced it will join the Exelixis and Roche clinical collaboration and participate in the
Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-02, a global phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with
3 Winning Stocks to Invest $2,500 Into Right Now | The Motley Fool
09:51am, Monday, 29'th Jun 2020
These great businesses have been money machines for investors over the long run.
